Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Search


Advanced search

»  News-Alert

Subscribe to our e-mail newsletter to get our latest news and dates by e-mail

Subscribe / Unsubscribe


Software-Update: Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus V 1.3 for all KRYPTOR systems

Thermo Scientific Biomarkers has brought an Update of the CE marked prenatal screening software B·R·A·H·M·S Fast Screen pre I plus onto the market. The new version 1.3 of the prenatal screening software is available as of November 2011 - currently deliverable in the following languages: German, English and French.


Thermo Scientific Biomarkers launches new assay: Thermo Scientific B·R·A·H·M·S TRAK human KRYPTOR

Thermo Scientific Biomarkers launched the automated TRAK human KRYPTOR assay in countries that accept CE certification. This assay is highly specific for the autoimmune disorder Graves´ disease.


B·R·A·H·M·S-Forum: Workshop on thyroid cancer big success

Hennigsdorf / Berlin 24.11.2009. At the invitation of B·R·A·H·M·S over 50 medics and scientists made their way to Berlin on November 6 and 7 to get an update on most recent developments in the field of thyroid cancer.


Competition Authorities approve Acquisition of B·R·A·H·M·S by Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) has acquired all of the shares of B·R·A·H·M·S Holding GmbH. The contractual merger resulting from this transaction was announced at the beginning of September. After a four-week inspection, the competent supervisory authorities have now also consented to the agreement.


The struggle against bacterial resistance and increasing medical costs:

ProHOSP study demonstrates the value of Procalcitonin marker for lower respiratory tract infections


B·R·A·H·M·S and Thermo Fischer Scientific join forces to create a leader in specialty diagnostics.

B·R·A·H·M·S announces the signature of a Share Purchase Agreement (SPA) with Thermo Fisher Scientific Inc. (NYSE: TMO) for 100% of the share capital of B·R·A·H·M·S Holding GmbH in the amount of EUR 330 million (approx. USD 470 million) including debt and other liabilities. The transaction, which is subject to applicable regulatory approvals, is expected to be closed in late September.


Company Event on Friday, September 4th 2009!


BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.


New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).


BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests

Berlin, Germany / Nimes, France / Richmond, CA, U.S.A., June 22, 2009. Diagnostics company BRAHMS Aktiengesellschaft, Cezanne and Lumiphore Inc., a biotechnology leader from California, announced that they have signed an agreement on incorporation of Lumiphore’s Lumi4®-Tb complexes in BRAHMS diagnostic tests.

Page: 2